Skip to main content
. 2024 Nov 8;11(1):62–65. doi: 10.1016/j.aace.2024.10.007

Table 2.

Summary of Arterial Embolization Procedures for the Management of Insulinoma (Until December 2023)

Reference No. of cases Age (y) Gender Tumor size (mm) Tumor location Reason for the choice of treatment No. of treatments Postprocedure complications Follow-up (mo) Recurrence Time of recurrence (mo)
Moore 8 1 38 F 20 H SF 1 Low back pain, nausea, Increase in liver enzymes 11 No -
Uflacker 13 2 56/49 M/M 18/20 H/B SR/SE 2/1 Abdominal pain, hyperamylasaemia/none 18/40 No -
Rott 14 1 84 F 14 H SR 1 Mild pancreatitis and pain, transitory mild diabetes 12 No -
Peppa 11 1 30 M 30 PP DR 1 Abdominal pain 12 Yes 12
Balawejder 15 1 48 F 22 UP SR 1 None N/A Yes 5
Mele 2 1 72 F 17 H C 2 Mild pancreatitis and pain 108 Yes 48
Donohoe 9 2 83/53 M/M 32/NR UP/UP C/SR 1/1 None/none 1/1 No/No -
Our case 1 80 M 37 H, UP SR, C 1 None 5 No -
Total 10 59,3 ± 19,3 6 M/4 F 23,3 ± 7,7 H = 5; B = 1; UP = 4; PP = 1 SR = 5; C = 3; SF = 1; SE = 1; DR = 1 1 in 8 cases None in 5 cases 23,1 ± 33,9 3 (30%) 22 ± 23

Abbreviations: B = body; C = comorbidities; DR = disease recurrence; H = head; NR = no report; PP = peripancreatic; SE = surgical emergency; SF = surgical failure; SR = surgery refusal; UP = uncinate process.

Cumulative data are indicated as mean ± SD, and as absolute values with percentages in parentheses.

Source: Own elaboration.